This study aimed to evaluate the capacity of hypocalcemic analogues of 1α,25-dihydroxyvitamin D 2 (1,25D2) and 1α,25-dihydroxyvitamin D 3 (1,25D3) to inhibit regrowth and regulate the stemness-related gene expression in colon cancer cells undergoing renewal after exposure to 5-fluorouracil (5-FU). All of the tested analogues of 1,25D2 equally potently decreased the clonogenicity and the proliferative activity of HT-29 cells which survived the exposure to 5-FU, but differently regulated gene expression of these cells during their renewal. 1,25D2 and analogues (PRI-1907 and PRI-1917), as well as 1,25D3 and analogue PRI-2191, decreased the relative expression level of several stemness-related genes, such as NANOG, OCT3/4, PROM1, SOX2, ALDHA1, CXCR4, in HT-29/5-FU cells during their renewal, in comparison to untreated HT-29/5-FU cells. The other 1,25D2 analogues (PRI-1906 and PRI-1916) were not capable of downregulating the expression of these stemness-related genes as the analogues PRI-1907 and PRI-1917 did. All of the tested vitamin D analogues upregulated CDH1, the gene encoding E-cadherin associated with epithelial phenotype. Out of the series of analogues studied, side-chain branched analogues of 1,25D2 (PRI-1907, PRI-1917 and the analogue of 1,25D3 (PRI-2191) might be used to target cancer cells with stem-like phenotypes that survive conventional chemotherapy.
Introduction
Colorectal cancer is the fourth cause of malignancy-related deaths worldwide [1] . Conventional chemotherapy regimens, such as 5-fluorouracil (5-FU)/leucovorin/oxaliplatin (FOLFOX), 5-FU/ leucovorin/irinotecan (FOLFIRI) or capecitabine/oxaliplatin (CapeOx), often fail to eradicate advanced colorectal cancer. It is assumed that to prevent cancer recurrence after conventional chemotherapy, new therapies should be developed to target cancer stem cells (CSC)/tumor initiating cells (TIC) that are more resistant to conventional cytoreductive drugs than differentiated cancer cells and are capable of initiating tumor regrowth [2] [3] [4] . So far, new therapeutic approaches have been focused on inducing differentiation of CSC [5, 6] and sensitizing CSC for chemotherapy [7] .
Active forms of vitamin D and its analogues have inhibitory effects on Wnt/β-catenin, Hedgehog, Notch and TGF-β signalling pathways, which are involved in self-renewal and differentiation of normal stem cells but are also aberrantly activated in different solid tumors [8] . Therefore, vitamin D and its analogues could be considered as candidate agents to target CSC/TIC, which initiate cancer recurrence after chemotherapy. Multiple studies suggest that vitamin D plays a role in cancer prevention [9] [10] [11] [12] [13] . A low level of vitamin D in the blood serum is associated with a higher risk of developing advanced adenomas [14] . There is a correlation between the low level of vitamin D and the risk of developing colorectal cancer [15] [16] [17] [18] . Studies on mice showed that the administration of vitamin D analogues alone [19] , and also in the combination with the cytoreductive drug 5-FU [20, 21] , retarded tumor growth. Although the combined treatment with cytostatics and vitamin D was more effective than the treatment with a cytostatic alone, the simultaneous administration of cytoreductive drugs and vitamin D in the combined treatment schedules led to increased toxicity [22] [23] [24] . Furthermore, vitamin D analogues block the cell cycle at the G1/S transition that prevents cancer cells from entering S-phase [20, 24] . Cancer cells that are prevented by vitamin D from entering the S-phase of the cell cycle may become more resistant to cytoreductive drugs than rapidly dividing cells [20, 24] . Since the combined use of vitamin D analogues and cytoreductive drugs can be associated with increased toxicity, a sequential administration of vitamin D analogues following the administration of cytoreductive drugs could be considered as an alternative treatment strategy aimed to counteract tumor regrowth after conventional chemotherapy. An additional argument in favor of the sequential vitamin D administration is based on the observation that the expression of stemness-related genes was highly increased in colorectal cancer cells that resisted the treatment with 5-FU in comparison to the chemonaive cells. Selected vitamin D analogues decreased the expression of stemness-related genes in 5-FU-pretreated colorectal cancer cells [25] , PRI-2191 and PRI-1906 used at a very low concentration induced the loss of a stem-like phenotype and decreased the clonogenicity and proliferative activity of HT-29 cells undergoing renewal after exposure to 5-FU [25] .
In our current efforts to optimize the structure of vitamin D analogues to increase their anti-cancer potential, we have compared the activity of our recently obtained side-chain modified geometric analogues of 1α,25-dihydroxyvitamin D 2 (1,25D2), PRI-1916 and PRI-1917 , with the previously obtained hypocalcemic analogues PRI-1906 and PRI-1907 , as well with 1α,25-dihydroxyvitamin D 3 (1,25D3) and its low-calcemic analogue PRI-2191 showing high anti-proliferative activity. The structures of vitamin D active metabolites and analogues are shown in Figure 1 . Our present study was aimed at identifying vitamin D analogues optimally suited to counteract both the regrowth and stemness of colorectal cancer cells refractory to the treatment with 5-FU. 
Results

The Effect of
The Effect of Vitamin D Analogues on the Proliferative Activity and the Expression of Cancer Stem Cell (CSC) Surface Markers in HT-29 Cells Undergoing Renewal after Treatment with 5-FU
The exposure to 5-FU decreased the expression of CD133 and CXCR4 cell surface markers. Vitamin D analogues did not affect much the expression of CXCR4 and CD133 by HT-29/5-FU cells undergoing renewal during four-day culture after cell passage performed on the third day after 5-FU removal from the culture (Figure 4 ). The proliferative activity of HT-29/5-FU cells was evaluated on the basis of Ki-67 expression. Ki-67 protein is involved in ribosomal RNA transcription. Since Ki-67 is present at all the active cell cycle phases (G1, S, G2, and mitosis) but is strongly downregulated in resting cells (G0), Ki-67 is used as a cell proliferation marker [26, 27] ) for four days after cell passage, as compared to the level in HT-29/5-FU cells cultured in medium only for four days after cell passage. GAPDH was used as an endogenous control. Fold differences were calculated using the ΔΔCt method and are expressed as a range that is a result of incorporating the standard deviation of the ΔΔCt value into the fold-difference calculation. The graphs show fold change of the relative mRNA expression level of genes related to (A) cancer stem cells (CSC), stemness; (B) endothelial-mesenchymal transition (EMT), invasiveness, angiogenesis; (C) apoptosis, survival, differentiation and epithelial phenotype; (D) oncogenesis and proliferation in HT-29/5-FU exposed to vitamin D analogue (100 nM) for four days after cell passage, as compared to the level in HT-29/5-FU cells cultured in medium only for four days after cell passage. GAPDH was used as an endogenous control. Fold differences were calculated using the ∆∆C t method and are expressed as a range that is a result of incorporating the standard deviation of the ∆∆C t value into the fold-difference calculation.
SOX2 ( Figure 6A ). In addition, both PRI-1906 and PRI-1916 more potently upregulated the relative expression level of ALCAM, BMI1, CD44, EPCAM, LGR5 and NOTCH1 than the other tested vitamin D analogues, and upregulated the relative expression level of NANOG. If 18S RNA served as an endogenous control in the gene expression analysis, PRI-1906 augmented the expression of such genes as HIF1A, HIF2A, MTOR, VEGFA, VEGFB and CDH1 more efficiently than 1,25D2 and its analogues PRI-1907 and PRI-1917, but similarly to PRI-1916 ( Figure 6B ). 
Discussion
Cancer stem cells are relatively more resistant to cytoreductive drugs than more differentiated cells; therefore, they are preferentially spared by conventional chemotherapy [28] [29] [30] [31] . Furthermore, due to cancer cell plasticity, heterogeneous cancer cells acquire stem-like properties in response to cytoreductive agents [4, [32] [33] [34] . Therefore, new agents should be found which could target cancer cells displaying stem-like features maintained or acquired after conventional chemotherapy. In this in the capability to regulate the expression level of CSC/stemness-associated genes in HT-29/5-FU cells undergoing renewal during four-day culture after cells passage and (B) more potently increased the relative expression level of several other genes. Fold differences were calculated using the ∆∆C t method and are expressed as a range that is a result of incorporating the standard deviation of the ∆∆C t value into the fold-difference calculation.
Cancer stem cells are relatively more resistant to cytoreductive drugs than more differentiated cells; therefore, they are preferentially spared by conventional chemotherapy [28] [29] [30] [31] . Furthermore, due to cancer cell plasticity, heterogeneous cancer cells acquire stem-like properties in response to cytoreductive agents [4, [32] [33] [34] . Therefore, new agents should be found which could target cancer cells displaying stem-like features maintained or acquired after conventional chemotherapy. In this study, we showed that the anti-cancer activity of vitamin D analogues of 1,25D3 (PRI-2191), as well as of 1,25D2 (PRI-1907 and PRI-1917) encompassed both the anti-proliferative effect and the modification of stemness-associated gene expression, leading to a shift from the stem-like phenotype toward a more differentiated phenotype. PRI-2191, PRI-1907 and PRI-1917 downregulated the expression of NANOG, OCT3/4 and SOX2, i.e., pluripotent stem cell-related genes involved in the stem cell renewal, which are aberrantly overexpressed in several cancers [35, 36] . Stemness-associated genes NANOG, OCT3/4 and SOX2 are involved in self-renewal activity of colorectal cancer cells [37] . It can be speculated that the downregulation of NANOG, OCT3/4 and SOX2 expression by PRI-2191, PRI-1907 or PRI-1917 might decrease the capacity of residual CSC to initiate cancer renewal after conventional chemotherapy.
We found that PRI-2191, PRI-1907 and PRI-1917 decreased ALDHA1 expression in HT-29/5-FU cells undergoing renewal. Aldehyde dehydrogenase 1 (ALDH1) is a marker for identification and tracking of colorectal CSC [38, 39] . ALDH1 oxidizes intracellular aldehydes and thereby is involved in the resistance to alkylating agents [28] . High ALDH1 expression correlates with a poor clinical outcome [40, 41] . ALDH1 expression induced after the chemotherapy may allow the acquisition of chemoresistance in residual cancers [42] . Our data suggest that PRI-2191, PRI-1907 and PRI-1917 might decrease chemoresistance of residual colon cancer cells after the chemotherapy due to the downregulation of ALDHA1 expression.
In our study, PRI-2191, PRI-1907 and PRI-1917 decreased the expression of CXCR4 and PROM1 encoding CSC markers CXCR4 and CD133, respectively. The stromal cell-derived factor-1 (SDF-1/CXCR4) axis is involved in delivering signals related to chemotaxis, cell survival and/or proliferation, and thereby plays an important role in EMT and tumor invasiveness [43, 44] . The co-expression of CXCR4 and CD133 in colon cancer may be associated with unfavorable prognosis [45, 46] . Our data show that PRI-2191, PRI-1907 and PRI-1917 might be used to induce the loss of stem-like phenotype, as well as to decrease chemotactic and proliferative activity of colon cancer cells refractory to the cytoreductive treatment.
All of the tested vitamin D analogues upregulated KLF4. Krüppel-like factor 4 (KLF4) is a zinc finger transcription factor that functions as a tumor suppressor or as an oncogene. In colon cancer stem cell-enriched spheroid cells, KLF4 acts as an oncogene [47] . However, loss of KLF4 was associated with worse disease-free survival in colon cancer patients [48] . KLF4 directly represses BMI1 transcription, and thereby regulates BMI1, which is required for colon cancer proliferation [49] . In our study, PRI-1906 and PRI-1916, but not other vitamin D analogues, substantially upregulated BMI1. In several carcinomas, including colon cancer, an overexpression of BMI1 is related to cancer aggressiveness [50] [51] [52] .
The tested vitamin D analogues augmented the expression of epithelial tissue stem cell-related genes LGR5 and SHH. Reports on LGR5's role in the survival and proliferation of colon cancer cells are confusing. The maintenance of CSC in spheroids required LGR5 activity [53] . On the other hand,
LGR5 was reported as a negative regulator of tumorigenicity due to antagonizing Wnt signalling. Paradoxically, LGR5 ablation increased colon cancer cell invasiveness and xenograft tumorigenicity [54] . Hedgehog signalling is involved in differentiation and renewal of the colonic lining epithelium rather than in cancer formation. It was reported that the viability and proliferation of well-differentiated HT-29 adenocarcinoma cell line depends on active Hedgehog signalling [55] .
Since the tested vitamin D analogues upregulate CDH1, they could be used to promote mesenchymal-to-epithelial transition and differentiation of residual colon cancer after conventional chemotherapy. It was reported that vitamin D3 promotes the differentiation of colon cancer cells by the induction of E-cadherin [5] . The tested vitamin D compounds, except for 1,25D2, upregulated MYC expression in spite of the concomitant upregulation of CDH1. Overexpression of c-MYC induces a neoplastic transformation in many types of cells [56] . However, c-MYC is a factor that has been shown to regulate stem cell exit from the epidermal stem cell compartment to become transit-amplifying cells that can undergo terminal differentiation [57] .
Vitamin D analogues upregulated EPHB4. The receptor tyrosine kinase EPHB4 has oncogenic activities in various cancers. In colorectal cancer patients, low tumor EPHB4 levels are associated with poor prognosis [58] . In animal models, EPHB receptors regulate cell proliferation and migration in the intestine. EPHB4 has tumor suppressor activities in intestinal tumorigenesis [59, 60] .
We found that the effect of vitamin D analogues on the expression of stemness-associated genes may promote drift of colon cancer cells from the stem-like phenotype to the more differentiated phenotype. The effect of vitamin D analogues on the gene expression in colon cancer cells undergoing renewal after cytoreductive treatment was ambiguous in some aspects. Although vitamin D analogues enhanced the expression of some genes related to angiogenesis and proliferation, in fact, the anti-proliferative effects of vitamin D prevailed over pro-proliferative effects in colon cancer cell cultures.
The selected analogue of 1,25D3 (PRI-2191), which previously showed hypocalcemic activity [61] , retained the potency of 1,25D3 to inhibit the proliferative activity of colon cancer cells. All of the tested analogues of 1,25D2, regardless of their side-chain length and geometry, were at least as potent inhibitors of the proliferative activity as the 1,25D2 itself. We found that PRI-1907 and PRI-1917 compared to 1,25D2, as well as PRI-2191 compared to 1,25D3, and similarly 1,25D2 compared to 1,25D3, did not differ in their capacity to regulate the relative gene expression level in colon cancer cells undergoing the renewal after the treatment with 5-FU. PRI-1906 and PRI-1916 differed from 1,25D2 and the other tested analogues in their effect on the relative expression level of stemness-related genes and particular genes associated with angiogenesis, invasiveness and proliferation in such cells. The effects of PRI-1906 and PRI-1916 on all of the tested genes were similar, except for GAPDH, SHH, MYC and OCT3/4. Our data suggest that the differences in the structure of vitamin D analogues are manifested in their different effects on the expression of genes that are involved in the maintenance of a stem-like phenotype in colon cancer cells refractory to cytoreductive treatment. [62] [63] [64] [65] . Samples of analogues were aliquoted to amber ampoules and dried down in a stream of argon. The samples were dissolved in absolute ethanol (99.8%) to obtain 20 µM stock solution. The solution was stored at´20˝C and diluted in a culture medium to a working concentration right before use.
Materials and Methods
Drugs and Analogues
5-
Cell Line
The moderately differentiated human colon adenocarcinoma cell line HT-29 was purchased from Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ, Braunschweig, Germany). Cells were cultured in McCoy's 5a culture medium (Lonza, Basel, Switzerland) supplemented with glutamine, 10% inactivated FBS (Biowest, Nuaillé, France) and antibiotics. Cells were cultured in humidified atmosphere at 37˝C and 5% CO 2 .
Selection of Cancer Cells Refractory to Treatment with 5-FU
HT-29 cells were seeded in 75-cm 2 flasks (Nunc, Rochester, NY, USA) at a cell density 85ˆ10 3 cells/mL of culture medium. After 4 h incubation, 5-FU was added at a working concentration of 6 µL/mL (46 µM). Cells were exposed to 5-FU for 24 h, and then the medium was replaced with a fresh medium without 5-FU. On the third day of culture after 5-FU removal, cells refractory to a single 5-FU treatment were collected using trypsin with EDTA (Trypsin-EDTA, Lonza, Basel, Switzerland). The collected cells were denominated as HT-29/5-FU cells.
Cultures of Cells Preselected with 5-FU
HT-29/5-FU cells collected on the third day after 5-FU removal from the culture were seeded in 75-cm 2 flasks in the absence or in the presence of 1,25D3, PRI-2191, 1,25D2, PRI-1906 , PRI-1916 , PRI-1907 or PRI-1917 , each added at a concentration of 100 nM. Fresh medium with or without vitamin D or analogues was replaced after 2 days. On the fourth day of the culture, cells were harvested using non-enzymatic cell dissociation solution Cellstripper ® (Corning, Manassas, VA, USA).
Clonogenicity Assay
HT-29/5-FU cells collected on the third day after 5-FU removal from the culture were plated on 35 mm diameter Petri dishes at a concentration of 5ˆ10 2 cells/dish, with or without 1,25D3, PRI-2191, 1,25D2, PRI-1906, PRI-1916, PRI-1907 or PRI-1917, added at a concentration 100 nM. On the 10th day of culture, cell colonies were fixed and stained with crystal violet in methanol. Colonies were counted under a microscope at a 100-fold magnification.
Antibodies and Flow Cytometry
PE-Cy7-anti-CXCR4 and Alexa-Fluor-647-anti-Ki67 was purchased from BD Biosciences (San Jose, CA, USA). PE-CD133/1 (AC133) was purchased from Miltenyi Biotec (Cologne, Germany). Following the labeling of cells with fluorochrome-conjugated monoclonal antibodies specific for extracellular markers, intracellular staining was performed using FoxP3 Staining Buffer Set (eBioscience, San Diego, CA, USA) according to the manufacturer's protocol. Flow cytometry was performed using the FACSAriaIII (BD Biosciences). Data was analyzed using FACSDiva software (BD Biosciences).
Gene Expression Analysis
Total RNA was extracted using TRI Reagent Solution (Ambion, Carlsbad, CA, USA) according to the manufacturer's protocol. Total RNA was transcribed to complementary DNA using high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). Quality of the RNA was confirmed with a NanoDrop ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA). The relative quantification of gene expression was analyzed in triplicates by TaqMan Array and a 7500 fast real-time PCR system (Applied Biosystems, Foster City, CA, USA). The C t comparative method was used with GAPDH or 18S RNA serving as an endogenous control. Data output was expressed as a fold-change of expression levels. Fold differences were calculated using the ∆∆C t method, expressed as a range that is a result of incorporating the standard deviation of the ∆∆C t value into the fold-difference calculation.
Statistics
Statistical significance was evaluated with one-way ANOVA with Bonferroni multicomparison post-test correction and with Dunnett's test using SPSS 14.0 (SPSS Inc., Kraków, Poland). p-Values < 0.05 were considered significant.
Conclusions
Our data suggest that the analogues of 1,25D2, PRI-1907 and PRI-1917 , and the analogue of 1,25D3 (PRI-2191), could be considered in further studies as candidate compounds to counteract cancer recurrence by decreasing the proliferative capacity of cells initiating tumor regrowth and by downregulation of the stemness-related genes, if applied sequentially after the treatment with conventional cytoreductive chemotherapy. PRI-1906 and PRI-1916 inhibit the regrowth of colon cancer cells refractory to the treatment with 5-FU, but do not share the capability of the other tested analogues (PRI-1907 and PRI-1917) to induce the downregulation of the stemness-related genes.
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